Publications by authors named "Sergio F de Lima Junior"
Clinical factors associated with severity in patients with inflammatory bowel disease in Brazil based on 2-year national registry data from GEDIIB.
Renata de Sá Brito Fróes Adriana Ribas Andrade Mikaell Alexandre Gouvea Faria Heitor Siffert Pereira de Souza Rogério Serafim Parra Sérgio Figueiredo de Lima Junior Roberto Luiz Kaiser Junior
Sci Rep
February 2024
Article Synopsis
- The Brazilian Organization for Crohn's Disease and Colitis (GEDIIB) created a national registry to study factors linked to the severity of inflammatory bowel disease (IBD) among Brazilian patients.
- The study included 1,179 patients, primarily diagnosed with ulcerative colitis (UC) or Crohn's Disease (CD), and found that many had extensive disease, with a significant portion needing biologic treatments.
- Factors like age, disease extent, and certain complications increased the severity of IBD, particularly for those with extensive colitis or specific disease behaviors.
Anti-TNF therapy for ulcerative colitis in Brazil: a comparative real-world national retrospective multicentric study from the Brazilian study group of IBD (GEDIIB).
Ligia Yukie Sassaki Daniela Oliveira Magro Rogerio Saad-Hossne Julio Pinheiro Baima Cristina Flores Sergio Figueiredo De Lima Junior
BMC Gastroenterol
May 2022
Article Synopsis
- Anti-TNF therapy has proven effective in treating ulcerative colitis (UC), but there's limited data on its impact on Brazilian patients; this study compares the efficacy of adalimumab (ADA) and infliximab (IFX) in achieving clinical and endoscopic remission after one year of treatment.
- Conducted across 24 centers, the study included 393 UC patients and utilized various statistical methods to analyze treatment outcomes, finding that IFX showed better clinical remission rates compared to ADA at 26 and 52 weeks.
- Results indicated a clinical remission rate of 82.82% at week 52, with IFX patients experiencing fewer instances of loss of response, although endoscopic remission rates did not significantly differ between the
Tumor necrosis factor (TNF) alpha and interleukin (IL) 18 genes polymorphisms are correlated with susceptibility to HPV infection in patients with and without cervical intraepithelial lesion.
Mayara C Mansur Tavares Sérgio F de Lima Júnior Antonio V C Coelho Trícia Ruschelle N M Marques Diêgo Henrique T de Araújo
Ann Hum Biol
May 2016
Background: The Human Papillomavirus (HPV) predisposes 500 000 women to cervical cancer. Host genetic background may facilitate virus persistence in the uterine cervix. Polymorphisms in regulatory and coding regions of cytokine genes have been associated with susceptibility to some human diseases.
View Article and Find Full Text PDFChlamydia trachomatis (CT) is the most common bacterial cause of sexually transmitted disease. High-risk human papillomavirus (HR-HPV) is considered the main etiological agent for cervical neoplasia. Evidences showed that the presence of co-infection of CT and HR-HPV plays a central role in the etiology of cervical intraepithelial neoplasia (CIN) and cervical cancer.
View Article and Find Full Text PDF